RxDoctor Payments Data

Rose Wright

Family · Stamford, NYNPI 1659476877

Payments from drug & device makers

$1,410in general payments, 2019–2025

Across 71 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$353
  • Pfizer$265
  • AbbVie$249
  • GSK$132
  • Otsuka America Pharmaceutical, Inc.$74
  • Exact Sciences$73
  • plus $264 from 8 others

What the payments were for

  • Food & beverage$1,410100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,410 in reported general payments places this provider in the 75th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$73,318
Medicare patients
281
Services billed
1,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$77,322
OzempicSemaglutide49$62,592
FarxigaDapagliflozin Propanediol28$39,767
Breo ElliptaFluticasone/Vilanterol26$22,073
TrulicityDulaglutide17$19,229
XareltoRivaroxaban22$17,587
JardianceEmpagliflozin16$15,170
JanuviaSitagliptin Phosphate15$15,071
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$12,267
Arnuity ElliptaFluticasone Furoate48$10,210
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,414
Albuterol Sulfate HfaAlbuterol Sulfate120$7,215
Sucralfate28$7,077
BreynaBudesonide/Formoterol Fumarate24$6,259
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$5,618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$265$77,32287 claims
Novo NordiskOzempic$48$62,59249 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$353$50,60353 claims
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta$132$44,55088 claims
Lilly USA, LLCTrulicity$50$19,22917 claims
Johnson & JohnsonXarelto$18$17,58722 claims
Boehringer IngelheimJardiance$28$15,17016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,883 family providers in New York.

Other family in Stamford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →